Sirona Dental Systems - frühere Siemens-Dentalsparte - 500 Beiträge pro Seite

[R-BgO]

04.12.2009 12:31
Sirona Reports Fiscal 2009 Fourth Quarter and Full Year 2009 Results

* Fourth quarter 2009 revenues increased to $188.2 million, up 4.2% year-over-year and up 8.4% on a constant currency basis. Fiscal Year 2009 revenues increased 1.3% constant currency, exceeding guidance.
* Fiscal Year 2009 operating income excluding amortization expense totaled $156.6 million, exceeding guidance.
* Cash flow from Operations was $119.9 million in Fiscal Year 2009, up 26.6% compared to Fiscal Year 2008.
* Sirona announces Fiscal Year 2010 guidance.

Sirona (Nasdaq: SIRO), the dental technology leader, today announced its financial results for the quarter and fiscal year ended September 30, 2009.

Chairman, President&CEO, Jost Fischer commented; "We are pleased to report another year of solid performance for Sirona and note that we finished with robust fourth quarter constant currency revenue growth of 8.4%. Despite the weak global economy, Sirona was able to grow constant currency revenues in fiscal 2009, driven by our innovative high-tech product line. During the year, the Company introduced breakthrough advancements in dental care, led by the CEREC AC. Our operating cash flow increased 26.6% to $119.9 million, and we reduced our net debt by $110.0 million. These results demonstrate the strength and resilience of our diversified business model. We are well positioned to compete successfully in fiscal 2010, backed by an innovative product offering, and a strong global sales and service infrastructure."

Fourth Quarter Fiscal 2009 vs. Fourth Quarter Fiscal 2008 Financial Results

Revenue was $188.2 million, an increase of $7.6 million or 4.2% (up 8.4% on a constant currency basis), with growth rates for the Company's business segments as follows: CAD/CAM increased 35.3% (up 40.1% constant currency); Instruments increased 2.3% (up 7.7% constant currency); Imaging Systems declined 5.5% (down 2.7% constant currency); and Treatment Centers declined 15.0% (down 10.4% constant currency). Revenue in the United States increased by 32.1%, particularly driven by CAD/CAM sales which benefited from strong interest in the CEREC AC and the AC trade-in program. Outside the United States, revenue declined 5.0% (flat constant currency).

Gross profit was $92.0 million, up $10.6 million compared to prior year. Gross profit margin was 48.9% in the fourth quarter of 2009 compared to 45.1% in the prior year. The gross profit margin expansion was driven by higher CAD/CAM sales, lower levels of amortization expense, and the strengthening of the US dollar relative to the Euro.

Fourth quarter 2009 operating income excluding amortization expense was $43.2 million (operating income of $24.7 million plus amortization expense of $18.6 million), compared to $33.1 million (operating income of $10.1 million plus amortization expense of $22.9 million) in the prior year. Fourth quarter 2009 operating income included restructuring expenses in the amount of $3.7 million.

Net income for the fourth quarter of 2009 was $26.7 million, or $0.476 per diluted share, compared to a loss of $5.2 million, or $0.09 per diluted share, for the fourth quarter of 2008. Fourth quarter 2009 earnings per share included $0.39 of amortization and depreciation expense attributable to the write-up in value of assets due to purchase accounting, a gain of $0.04 related to the revaluation of the Patterson exclusivity fee, a gain of $0.03 resulting from the revaluation of short-term intra-group loans, a $0.065 restructuring charge and a $0.03 one-time, non-cash gain.

For the fourth quarter of 2008, earnings per share included $0.38 of amortization and depreciation expense attributable to the write-up in value of assets due to purchase accounting, a loss of $0.11 related to the revaluation of the Patterson exclusivity fee and an $0.08 loss resulting from the revaluation of short-term intra-group loans.

The effective tax rate for fiscal 2009 was 14.7%.

At September 30, 2009, the Company had cash and cash equivalents of $181.1 million and total debt of $474.9 million, resulting in net debt of $293.8 million. This compares to net debt of $403.8 million at September 30, 2008. The decrease in net debt was driven by strong cash flow from operations, and lower tax and interest payments in the 2009 fiscal year. In May of 2009, the Company paid back the first scheduled debt repayment of $79 million, six months ahead of schedule.

Fiscal 2009 vs. Fiscal 2008 Financial Results

Revenue was $713.3 million, a decrease of $43.8 million, or 5.8% (up 1.3% constant currency) with growth rates for the Company's business segments as follows: CAD/CAM increased 3.4% (up 9.3% constant currency); Instruments declined 9.1% (up 0.5% constant currency); Treatment Centers declined 9.7% (flat constant currency); and Imaging Systems declined 10.7% (down 5.4% constant currency). Revenue in the United States was flat compared to prior year. Outside the United States, revenue declined 8.2% (up 1.8% constant currency) benefiting from growth in Germany and with mixed performance across the various countries.

Gross profit increased by $0.5 million to $346.1 million, up 0.2%. Gross profit margin of 48.5% was up 290 basis points compared to the prior year, mainly driven by lower levels of deal related amortization, a favorable product mix shift, and the strengthening of the US dollar relative to the Euro.

2009 operating income excluding amortization expense was $156.6 million (operating income of $85.1 million plus amortization expense of $71.5 million). This compares to 2008 operating income excluding amortization expense of $155.4 million (operating income of $63.8 million plus amortization expense of $91.6 million). Operating income in fiscal 2009 included restructuring expenses in the amount of $8.2 million.

Fiscal 2010 Guidance

The Company expects constant currency revenue growth of 4% to 6% in fiscal 2010. Operating income excluding amortization expense is expected to be in the range of $166 to $176 million.

[EPB]

Z A H N A R Z T

[R-BgO]

08.02.2010 12:33
Sirona Reports Fiscal 2010 First Quarter Results

* Revenue was $214.8 million, an increase of 19.5% compared to prior year, or up 10.9% on a constant currency basis.
* Operating income excluding amortization expense totaled $59.6 million, up 51.5% versus $39.4 million in the prior year.
* Cash flow from Operations was $40.6 million, compared to ($1.6) million in the prior year.
* Sirona updates guidance.

Sirona (Nasdaq: SIRO), the dental technology leader, today announced its financial results for the quarter ended December 31, 2009.

First Quarter Fiscal 2010 vs. First Quarter Fiscal 2009 Financial Results

Revenue was $214.8 million, an increase of $35.1 million or 19.5% (up 10.9% on a constant currency basis), with growth rates for the Company's business segments as follows: CAD/CAM increased 37.5% (up 29.3% constant currency); Instruments increased 19.0% (up 6.7% constant currency); Imaging Systems increased 9.2% (up 3.7% constant currency); and Treatment Centers increased 12.2% (up 0.5% constant currency). Revenue in the United States increased by 12.1% driven by the CAD/CAM and Imaging segments. Outside the United States, revenue increased by 23.3% (up 10.4% constant currency), driven by strength in Germany, Australia, Canada and Japan.

Gross profit was $112.4 million, up $25.4 million compared to prior year. Gross profit margin was 52.3% in the first quarter of fiscal 2010, compared to 48.4% in the prior year. The gross profit margin expansion was driven by product and regional mix and lower levels of amortization expense.

First quarter 2010 operating income excluding amortization expense was $59.6 million (operating income of $43.5 million plus amortization expense of $16.2 million), compared to $39.4 million (operating income of $21.8 million plus amortization expense of $17.6 million) in the prior year.

Net income for the first quarter of 2010 was $31.2 million, or $0.55 per diluted share, compared to $5.6 million, or $0.10 per diluted share in the prior year period. First quarter 2010 earnings per share included $0.22 of amortization and depreciation expense attributable to the write-up in value of assets due to purchase accounting, a loss of $0.02 related to the revaluation of the Patterson exclusivity fee, and a loss of $0.02 resulting from the revaluation of short-term intra-group loans. For the first quarter of 2009, earnings per share included $0.22 of amortization and depreciation expense attributable to the write-up in value of assets due to purchase accounting, a loss of $0.03 related to the revaluation of the Patterson exclusivity fee, a $0.02 loss resulting from the revaluation of short-term intra-group loans and a $0.01 gain on sale of an asset.

At December 31, 2009, the Company had cash and cash equivalents of $215.9 million and total debt of $470.1 million, resulting in net debt of $254.2 million. This compares to net debt of $293.8 million at September 30, 2009. The decrease in net debt was driven by strong cash flow from operations.

Chairman, President&CEO, Jost Fischer commented; "We are pleased with our exceptionally strong performance in the first quarter. Sirona's top line growth was driven by our recent innovative product launches and our technologically advanced product portfolio. The bottom line benefited from robust sales growth, margin expansion, expense management initiatives and deleveraging. We are pleased with our results and are confident in the prospects of our business."

Fiscal 2010 Guidance Update

The Company expects to achieve revenue growth at the higher end of its fiscal 2010 guidance range of 4% to 6%. Operating income excluding amortization expense is expected to be in the range of $170 to $176 million, compared to the previous range of $166 million to $176 million.

Conference Call/Webcast Information

Sirona will hold a conference call to discuss its financial results at 8:30 a.m. Eastern Time on February 8, 2010. The teleconference can be accessed by calling [phone] (domestic) or [phone] (international) using passcode # 57202316. The webcast will be available via the Internet at www.sirona.com and a presentation relating to the call will be available on our website. A replay of the conference call will be available through February 15, 2010 by calling [phone] (domestic) or [phone] (international) using passcode # 86135161. A web archive will be available for 30 days at www.sirona.com.

[R-BgO]

7.02.2010 15:26
Sirona Dental Systems Prices 7.25mm Secondary Share Offering


Sirona Dental Systems, Inc. ("Sirona") (Nasdaq: SIRO) today announced the pricing of the previously announced public offering by Sirona Holdings Luxco S.C.A. of 7,000,000 shares of common stock and 250,000 shares by Jeffrey T. Slovin, at a price to the public of $35.35 per share. The offering is expected to close on February 22, 2010 subject to customary closing conditions. Sirona Dental Systems, Inc. will not receive any proceeds from this sale of its common stock. One of the selling stockholders, Sirona Holdings Luxco S.C.A., has also granted the underwriter a 30-day option to purchase up to 1,050,000 additional shares of common stock.

Barclays Capital Inc. is the sole underwriter of the offering. The offering will be made only by means of a prospectus supplement and accompanying base prospectus, copies of which may be obtained from:

Barclays Capital Inc., c/o Broadridge, Integrated Distribution Services, 1155 Long Island Avenue, Edgewood, New York 11717; [e-mail] (phone: [phone]). A copy of the prospectus supplement and accompanying base prospectus may also be obtained at no charge at the U.S. Securities and Exchange Commission's website, at http://www.sec.gov.

The shelf registration statement relating to the foregoing has previously been filed with, and declared effective by the U.S. Securities and Exchange Commission. This press release does not constitute an offer to sell or a solicitation of an offer to buy the shares of Sirona's common stock or any other securities, nor will there be any sale of the shares of Sirona's common stock or any other securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

[R-BgO]

05.05.2010 12:31
Sirona Reports Fiscal 2010 Second Quarter Results


* Revenue was $190.1 million, an increase of 15.4% compared to prior year, or up 11.0% on a constant currency basis.
* Operating income excluding amortization expense was $46.1 million, up 47.2% versus $31.3 million in the prior year.
* Cash flow from Operations was $34.2 million, compared to $23.4 million in the prior year quarter.
* Early debt repayment of $78.1 million.
* Sirona increases FY10 guidance - revenue growth of 6% to 8% constant currency (prev. 4% to 6%) and operating income excluding amortization expense of $178 to $184 million (prev. $170 to $176 million).


Sirona (Nasdaq: SIRO), the dental technology leader, today announced its financial results for the three and six months ended March 31, 2010.

Second Quarter Fiscal 2010 vs. Second Quarter Fiscal 2009 Financial Results

Revenue was $190.1 million, an increase of $25.3 million or 15.4% (up 11.0% on a constant currency basis), with growth rates for the Company's business segments as follows: Instruments increased 22.0% (up 15.1% constant currency); Treatment Centers increased 20.7% (up 13.9% constant currency); Imaging Systems increased 20.4% (up 16.6% constant currency); and CAD/CAM increased 6.3% (up 3.4% constant currency). Revenue in the United States increased by 7.7%, particularly driven by strong sales of our Galileos 3D imaging system. Outside the United States, revenue increased by 19.2% (up 12.5% constant currency), driven by strength in Germany and Australia.

Gross profit was $99.3 million, up $19.0 million. Gross profit margin was 52.2% in the second quarter of Fiscal 2010, compared to 48.7% in the prior year. The gross profit margin expansion was the result of product and regional mix and lower levels of amortization expense.

Second quarter 2010 operating income excluding amortization expense was $46.1 million (operating income of $30.6 million plus amortization expense of $15.5 million), compared to $31.3 million (operating income of $13.7 million plus amortization expense of $17.6 million) in the prior year.

Net income for the second quarter of 2010 was $17.5 million, or $0.31 per diluted share, compared to $0.6 million, or $0.01 per diluted share in the prior year period. Second quarter 2010 earnings per share included $0.21 of amortization and depreciation expense attributable to the write-up in value of assets due to purchase accounting, a loss of $0.07 related to the revaluation of the Patterson exclusivity fee, a loss of $0.06 resulting from the revaluation of short-term intra-group loans and a $0.01 gain on the sale of a subsidiary. For the second quarter of 2009, earnings per share included $0.23 of amortization and depreciation expense attributable to the write-up in value of assets due to purchase accounting, a loss of $0.05 related to the revaluation of the Patterson exclusivity fee, a $0.03 loss resulting from the revaluation of short-term intra-group loans and a $0.04 restructuring expense.

At March 31, 2010, the Company had cash and cash equivalents of $162.4 million and total debt of $367.3 million, resulting in net debt of $204.9 million. This compares to net debt of $293.8 million at September 30, 2009. The decrease in net debt was driven by strong cash flow from operations. In March, the Company paid back the second scheduled debt repayment of $78.1 million, eight months ahead of schedule.

Chairman, President&CEO, Jost Fischer commented; "We are pleased with our strong performance in the second quarter. Our innovative product launches and technologically advanced portfolio continue to drive our performance. This was highlighted by robust sales of our Galileos 3D imaging system, which benefited from heightened interest in our Galileos CEREC integration. Our bottom line benefited from strong sales growth, margin expansion and deleveraging. As a result of our first half 2010 performance, and our confidence in the remainder of the year, we are increasing our Fiscal 2010 guidance."

Fiscal 2010 Guidance Update

The Company expects to achieve constant currency revenue growth in the range of 6% to 8% in Fiscal 2010, up from the previous guidance range of 4% to 6%. Operating income excluding amortization expense is expected to be in the range of $178 to $184 million, up from the previous guidance range of $170 million to $176 million.

First Half Fiscal 2010 vs. First Half Fiscal 2010 Financial Results

Revenue was $405.0 million, an increase of $60.4 million or up 17.5% (up 10.9% constant currency) with growth rates for the Company's business segments as follows: CAD/CAM Systems increased 20.8% (up 15.5% constant currency); Instruments increased 20.4% (up 10.6% constant currency); Treatment Centers increased 16.1% (up 6.6% constant currency); and Imaging Systems increased 14.1% (up 9.2% constant currency). Revenue in the United States increased 10.0%. Outside the United States, revenue increased 21.4% (up 11.3% constant currency) driven by solid performance in Germany and Asia Pacific.

Gross profit increased by $44.4 million to $211.7 million, up 26.5%. Gross profit margins expanded 370 basis points to 52.3 percent, due to product and regional mix and lower levels of amortization expense.

First half 2010 operating income excluding amortization expense was $105.8 million (operating income of $74.1 million plus amortization expense of $31.7 million), compared to $70.7 million (operating income of $35.5 million plus amortization expense of $35.2 million) in the prior year. First half 2009 results included a $2.8 million restructuring expense.

[R-BgO]

Q3:


* Revenues were $182.4 million, an increase of 1.0% compared to prior year, or up 6.0% on a constant currency basis.
* Operating income excluding amortization expense was $45.3 million, up 6.2% year-over-year.
* Cash flow from Operations was $61.2 million, up 14.2% compared to $53.5 million in the prior year quarter.
* FY10 Guidance Update: Constant currency revenue growth expected to reach the upper end of the 6% to 8% guidance range. Operating income excluding amortization increased to $186 to $190 million (prev. $178 to $184 million).

Sirona (Nasdaq: SIRO), the dental technology leader, today announced its financial results for the three and nine months ended June 30, 2010.

Third Quarter Fiscal 2010 vs. Third Quarter Fiscal 2009 Financial Results

Revenue was $182.4 million, an increase of $1.8 million or up 1.0% (up 6.0% on a constant currency basis), with growth rates for the Company's business segments as follows: Imaging Systems increased 17.7% (up 22.0% constant currency); CAD CAM increased 0.1% (up 4.3% constant currency); Instruments declined 4.8% (up 1.6% constant currency); and Treatment Centers declined 15.3% (down 9.6% constant currency). Revenue in the United States increased 33.7%, driven by strong demand for our Galileos 3D imaging system and increased CAD CAM shipments in advance of the U.S. CEREC AC upgrade program. Outside the United States, revenue declined 10.2% (down 4.2% constant currency). In the third quarter of Fiscal 2009, international revenues benefited from sales at the biannual International Dental Show, resulting in a challenging comparison for Germany and other European countries in the third quarter of Fiscal 2010. Revenues in the Asia Pacific region showed solid growth, particularly in Japan, China and Australia.

Gross profit was $94.2 million, up $7.4 million. Gross profit margin was 51.6% in the third quarter of Fiscal 2010, compared to 48.1% in the prior year. The gross profit margin expansion was the result of product and regional mix, lower levels of amortization expense and a favorable currency impact.

Third quarter 2010 operating income excluding amortization expense was $45.3 million (operating income of $30.7 million plus amortization expense of $14.5 million), compared to $42.6 million (operating income of $24.9 million plus amortization expense of $17.7 million) in the prior year.

Net income for the third quarter of 2010 was $16.6 million, or $0.29 per diluted share, compared to $20.5 million, or $0.37 per diluted share in the prior year period. Third quarter 2010 earnings per share included $0.20 of amortization and depreciation expense attributable to the write-up in value of assets due to purchase accounting, a loss of $0.10 related to the revaluation of the Patterson exclusivity fee, a loss of $0.08 resulting from the revaluation of short-term intra-group loans and a $0.01 gain on the release of accrued restructuring expenses. For the third quarter of 2009, earnings per share included $0.24 of amortization and depreciation expense attributable to the write-up in value of assets due to purchase accounting, a gain of $0.07 related to the revaluation of the Patterson exclusivity fee, a $0.04 gain resulting from the revaluation of short-term intra-group loans, a $0.025 restructuring expense and a $0.016 gain on the sale of a business.

At June 30, 2010, the Company had cash and cash equivalents of $200.2 million and total debt of $345.4 million, resulting in net debt of $145.2 million. This compares to net debt of $293.8 million at September 30, 2009. The $148.6 million decrease in net debt was primarily driven by strong cash flow from operations.

Jost Fischer, Chairman, President and CEO of Sirona commented: "I am pleased with our third quarter operating performance as we delivered solid revenue, margin and record cash flow results. Sirona's innovative technology continues to perform in the marketplace, with particularly strong growth in our imaging segment, which was driven by considerable demand for our Galileos 3D imaging system. Year-to-date, our constant currency revenues have increased by 9% and our operating income plus amortization has increased by 33%. Looking out to the rest of the year, we expect positive revenue growth to continue and therefore we are increasing our guidance for fiscal 2010."

Mr. Fischer continued, "For the fourth quarter, revenues are expected to increase in the low to mid single digits on a constant currency basis. CAD CAM revenues are anticipated to be down compared to a very strong fourth quarter of fiscal 2009, with this result more than offset by growth in other segments. Today, we are increasing our operating income plus amortization guidance to $186 million to $190 million. For the full year, this would represent an increase of 19% to 21%."

Fiscal 2010 Guidance Update

The Company expects to achieve Fiscal 2010 constant currency revenue growth towards the upper end of the previously announced guidance range of 6% to 8%. Operating income excluding amortization expense is now expected to be in the range of $186 to $190 million, up from the previous guidance range of $178 million to $184 million.

[R-BgO]

Hat sich sehr schön entwickelt; hätte damals mehr kaufen sollen...

[R-BgO]

GJ-Zahlen kommen morgen

[Merger-one]

Sirona für anziehendes US-Wachstum gut aufgestellt:

Sirona Reports Fiscal 2013 Second Quarter Results
Second quarter revenues of $267.3 million, up 15.3% compared to prior year, or up 14.7% constant currency*.
Second quarter diluted earnings per share of $0.56 on a GAAP reported basis compared to $0.54 in the prior year. Second quarter non-GAAP adjusted EPS* of $0.75, up 11.3% compared to $0.67 in the prior year.
Management now anticipates FY13 constant currency revenue growth at 10% to 12% (previously 9% to 11%), and non-GAAP adjusted EPS* in the range of $3.36 to $3.43 (reflecting growth of approximately 11% to 13%, compared to previous guidance of $3.33 to $3.43).

Eine gute Firma mit nachhaltigen Wachstumsaussichten und dazu moderater Bewertung.

[R-BgO]

wie ein Uhrwerk: http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9N…

[R-BgO]

extrem gut gelaufen, aber auch extrem teuer

[R-BgO]

Antwort auf Beitrag Nr.: 50.027.880 von R-BgO am 22.06.15 22:36:30

das juckt Dentsply nicht; Übernahme:

http://www.handelsblatt.com/unternehmen/industrie/sirona-geh…

[Der_Paul]

Bin da etwa engagiert und könnte jetzt dicken Gewinn mitnehmen. Oder laufen lassen und Fusion abwarten?

[R-BgO]

Merger hat Anfang März geclosed

over-and-out

[R-BgO]

falls jemand wissen will, wie es weitergeht: Thread: Dentsply Sirona